skip to Main Content

Pamrevlumab Plus Chemo Under Exploration in Novel Pancreatic Cancer Trial Platform

Newsfeed image, light gray text on dark gray background
A new experimental treatment arm examining pamrevlumab in combination with gemcitabine and nab-paclitaxel (Abraxane) as a first- or second-line treatment for patients with metastatic pancreatic cancer has been added to the novel clinical trial platform Precision Promise, which is being conducted by the Pancreatic Cancer Action Network (PanCAN).
The addition of the new treatment arm to the platform marks the first investigative therapy to be offered as a frontline treatment on the study. As such, patients with newly diagnosed metastatic pancreatic cancer who are enrolled to the platform are now able to onto an investigative approach in the first line, and then move on to another experimental treatment in the second-line setting, should the first approach no longer be efficacious. Read more . . . 

Back To Top